[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 12, Issue 1 (1-2014) ::
Int J Radiat Res 2014, 12(1): 33-38 Back to browse issues page
New drug in neoadjuvant chemoradiation for rectal cancer
M. Aghili, M. Babaei , M. Ganjalikhani, F. Azmoodeh Ardalan
Department of Radiotherapy Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran , m-babaei@sina.tums.ac.ir
Abstract:   (7195 Views)

Background: In recent years, neoadjuvant chemoradiation and subsequent surgical resection with total mesorectal excision has been shown to increase local control with decreased toxicity. Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer. In this study we evaluated the efficacy a cox-2 inhibitor on pathologic response, sphincter preservation and acute toxicity during neoadjuvant chemoradiation. Materials and Methods: Thirty-six patients with Adenocarcinoma of rectum (up to 15 cm of anal verge) was enrolled in this phase 2 study. Patients were undergone endorectal ultrasound, abdomino-pelvic and chest CT scan for staging. Then received neoadjuvant concurrent chemo radiation (capecitabine 825 mg/m2 bid in combination with celecoxib 100 mg qid and Radiotherapy “50-50.4Gy/25-28fraction”).Surgery was done 6-8 weeks after Chemoradiation. Acute complications were scored by common toxicity criteria 3.0 and tumor response was graded by tumor regression grade. Results: Of 36 patients, total mesorectal excision was done in 30 patients. Tumor regression grade was reported as:8 patients(26.7%) had grade 0 or complete response, 10 patients (33.3%) had grade 1 or moderate response,9 patients(30%) had grade 2 or minimal response and 3 patients (10%) had grade 3 or poor response. Tumor down staging was 43.3% and Node down staging was 30.8%.No patient had skin reaction or cardio-vascular toxicity. Conclusion: Results indicate celecoxib in combination with neoadjuvant chemoradiation is safe and associated with low toxicity. This combination can promote pathologic complete response, tumor regression grade and T and N down staging in rectal adenocarcinoma.

Keywords: Rectal cancer, celecoxib, tumor regression, neoadjuvant chemoradiation
Full-Text [PDF 1072 kb]   (2013 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aghili M, Babaei M, Ganjalikhani M, Azmoodeh Ardalan F. New drug in neoadjuvant chemoradiation for rectal cancer. Int J Radiat Res. 2014; 12 (1) :33-38
URL: http://ijrr.com/article-1-1159-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 1 (1-2014) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4343